A study titled “Single‑Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study” interviewed 26 pulmonary arterial hypertension patients and 18 doctors from the A DUE clinical trial, who tested the single-pill combination therapy (macitentan+tadalafil) versus taking multiple pills daily.
Both patients and doctors agreed that taking one pill daily instead of multiple pills was easier, reduced stress around medication management, and improved adherence. The single-pill combination is now approved in several countries and supports shared decision-making between patients and doctors for pulmonary arterial hypertension treatment options.
Read more at this link on the NIH Library
Summary by Deger Kesimoglu, volunteer for the Alliance for Pulmonary Hypertension
Citation
Fan F, Davis S, Burbridge C, Chin K, Friberg M, Grünig E, Hughes M, Jansa P, Langan G, Linder J, Rafalski J, Rodriguez AA, Randall JA. Preferences for pulmonary arterial hypertension (PAH) medications: plain language summary on insights from interviews with patients and doctors in the A DUE phase 3 clinical study. Future Cardiol. 2025 Nov 4:1-12. doi: 10.1080/14796678.2025.2567782. Epub ahead of print. PMID: 41186272.